News Three more pharmas join OpenFold3 AI consortium Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.
News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
News NICE relents on Takeda colorectal cancer drug Fruzaqla Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.
News MSD aims to plug dengue fever vaccine gap in US MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Takeda CEO succession confirmed as Weber plans retirement Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.
News EMA seeks input on virtual alternative to animal test EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.